187 related articles for article (PubMed ID: 20576287)
1. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer.
Staff AC; Bock AJ; Becker C; Kempf T; Wollert KC; Davidson B
Gynecol Oncol; 2010 Sep; 118(3):237-43. PubMed ID: 20576287
[TBL] [Abstract][Full Text] [Related]
2. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer.
Staff AC; Trovik J; Eriksson AG; Wik E; Wollert KC; Kempf T; Salvesen HB
Clin Cancer Res; 2011 Jul; 17(14):4825-33. PubMed ID: 21616994
[TBL] [Abstract][Full Text] [Related]
3. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.
Khan SQ; Ng K; Dhillon O; Kelly D; Quinn P; Squire IB; Davies JE; Ng LL
Eur Heart J; 2009 May; 30(9):1057-65. PubMed ID: 19168526
[TBL] [Abstract][Full Text] [Related]
4. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
5. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure.
Kempf T; von Haehling S; Peter T; Allhoff T; Cicoira M; Doehner W; Ponikowski P; Filippatos GS; Rozentryt P; Drexler H; Anker SD; Wollert KC
J Am Coll Cardiol; 2007 Sep; 50(11):1054-60. PubMed ID: 17825714
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions.
Bock AJ; Stavnes HT; Kempf T; Tropè CG; Berner A; Davidson B; Staff AC
Int J Gynecol Cancer; 2010 Dec; 20(9):1448-55. PubMed ID: 21336029
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
8. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
9. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
[TBL] [Abstract][Full Text] [Related]
11. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.
Ødegaard E; Davidson B; Elgaaen BV; Fagerhol MK; Engh V; Onsrud M; Staff AC
Am J Obstet Gynecol; 2008 Apr; 198(4):418.e1-7. PubMed ID: 18241816
[TBL] [Abstract][Full Text] [Related]
12. Detection of serum transforming growth factor-alpha in patients of primary epithelial ovarian cancers by enzyme immunoassay.
Chien CH; Huang CC; Lin YH; Shen J; Chow SN
Gynecol Oncol; 1997 Sep; 66(3):405-10. PubMed ID: 9299253
[TBL] [Abstract][Full Text] [Related]
13. Serum C-reactive protein in the differential diagnosis of ovarian masses.
Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
[TBL] [Abstract][Full Text] [Related]
14. Plasma calprotectin concentrations in women with endometrial carcinoma.
Ni Bhriain H; Trovik J; Wik E; Stefansson IM; Akslen LA; Salvesen HB; Staff AC
Gynecol Oncol; 2009 Sep; 114(3):491-5. PubMed ID: 19577278
[TBL] [Abstract][Full Text] [Related]
15. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
16. Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study.
Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S
J Med Assoc Thai; 2009 Mar; 92(3):308-14. PubMed ID: 19301721
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome.
Wollert KC; Kempf T; Peter T; Olofsson S; James S; Johnston N; Lindahl B; Horn-Wichmann R; Brabant G; Simoons ML; Armstrong PW; Califf RM; Drexler H; Wallentin L
Circulation; 2007 Feb; 115(8):962-71. PubMed ID: 17283261
[TBL] [Abstract][Full Text] [Related]
18. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
[TBL] [Abstract][Full Text] [Related]
19. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction.
Kempf T; Björklund E; Olofsson S; Lindahl B; Allhoff T; Peter T; Tongers J; Wollert KC; Wallentin L
Eur Heart J; 2007 Dec; 28(23):2858-65. PubMed ID: 17977844
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic markers for early detection of ovarian cancer.
Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
